These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 18637896)

  • 1. A marked increase in serum soluble Fas ligand in drug-induced hypersensitivity syndrome.
    Tohyama M; Shirakata Y; Sayama K; Hashimoto K
    Br J Dermatol; 2008 Sep; 159(4):981-4. PubMed ID: 18637896
    [No Abstract]   [Full Text] [Related]  

  • 2. Increased soluble Fas ligand levels in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis preceding skin detachment.
    Murata J; Abe R; Shimizu H
    J Allergy Clin Immunol; 2008 Nov; 122(5):992-1000. PubMed ID: 18692887
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnostic role of soluble fas ligand secretion by peripheral blood mononuclear cells from patients with previous drug-induced blistering disease: a pilot study.
    Lan CC; Wu CS; Tsai PC; Chen GS
    Acta Derm Venereol; 2006; 86(3):215-8. PubMed ID: 16710577
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Kinetics and specificity of fas ligand induction in toxic epidermal necrolysis.
    Chang HY; Cooper ZA; Swetter SM; Marinkovich MP
    Arch Dermatol; 2004 Feb; 140(2):242-4. PubMed ID: 14967808
    [No Abstract]   [Full Text] [Related]  

  • 5. The influence of hepatic damage on serum soluble Fas ligand levels of patients with drug rashes.
    Tohyama M; Shirakata Y; Sayama K; Hashimoto K
    J Allergy Clin Immunol; 2009 Apr; 123(4):971-2; author reply 972. PubMed ID: 19348934
    [No Abstract]   [Full Text] [Related]  

  • 6. Toxic epidermal necrolysis and Stevens-Johnson syndrome: soluble Fas ligand involvement in the pathomechanisms of these diseases.
    Abe R
    J Dermatol Sci; 2008 Dec; 52(3):151-9. PubMed ID: 18657400
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stevens-Johnson syndrome and toxic epidermal necrolysis.
    Borchers AT; Lee JL; Naguwa SM; Cheema GS; Gershwin ME
    Autoimmun Rev; 2008 Sep; 7(8):598-605. PubMed ID: 18603022
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Toxic epidermal necrolysis treated with low-dose intravenous immunoglobulin: immunohistochemical study of Fas and Fas-ligand expression.
    Ito K; Hara H; Okada T; Shimojima H; Suzuki H
    Clin Exp Dermatol; 2004 Nov; 29(6):679-80. PubMed ID: 15550154
    [No Abstract]   [Full Text] [Related]  

  • 9. T-cell subsets in drug-induced toxic epidermal necrolysis.
    Hertl M; Merk HF; Bohlen H
    Arch Dermatol; 1992 Feb; 128(2):272. PubMed ID: 1590854
    [No Abstract]   [Full Text] [Related]  

  • 10. Delayed hypersensitivity in drug-induced toxic epidermal necrolysis.
    Roujeau JC; Bagot M; Revuz J; Touraine R
    Arch Dermatol; 1984 Nov; 120(11):1417-8. PubMed ID: 6497406
    [No Abstract]   [Full Text] [Related]  

  • 11. [Allergological studies of the Lyell syndrome].
    Schöpf E; Schulz KH; Kessler R; Taugner M; Braun W
    Z Hautkr; 1975 Oct; 50(20):865-73. PubMed ID: 769372
    [No Abstract]   [Full Text] [Related]  

  • 12. Toxic epidermal necrolysis (scalded skin syndrome). A case report.
    Berkel AI; Yuluğ N; Erkul I
    Turk J Pediatr; 1973 Oct; 15(4):186-94. PubMed ID: 4792844
    [No Abstract]   [Full Text] [Related]  

  • 13. Serum interleukin-13 levels are increased in patients with Stevens-Johnson syndrome/ toxic epidermal necrolysis but not in those with erythema multiforme.
    Quaglino P; Caproni M; Osella-Abate S; Torchia D; Comessatti A; Del Bianco E; Antiga E; Frezzolini A; Schena D; Marzano A; De Simone C; Parodi A; Fabbri P; Bernengo MG
    Br J Dermatol; 2008 Jan; 158(1):184-6. PubMed ID: 17941938
    [No Abstract]   [Full Text] [Related]  

  • 14. [Quantitative determination of serum proteins in allergic contact dermatitis and drug hypersensitivity with a reversed radial immunodiffusion test].
    Husz S; Berkó G; Szilagyi I
    Z Hautkr; 1976 May; 51(09):343-52. PubMed ID: 822617
    [No Abstract]   [Full Text] [Related]  

  • 15. A possible role of Fas-ligand-mediated "reverse signaling" in pathogenesis of rheumatoid arthritis and systemic lupus erythematosus.
    Telegina E; Reshetnyak T; Moshnikova A; Proussakova O; Zhukova A; Kuznetsova A; Ivanov A; Paltsev M; Beletsky I
    Immunol Lett; 2009 Jan; 122(1):12-7. PubMed ID: 19010354
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum DNase I, soluble Fas/FasL levels and cell surface Fas expression in patients with SLE: a possible explanation for the lack of efficacy of hrDNase I treatment.
    Tinazzi E; Puccetti A; Gerli R; Rigo A; Migliorini P; Simeoni S; Beri R; Dolcino M; Martinelli N; Corrocher R; Lunardi C
    Int Immunol; 2009 Mar; 21(3):237-43. PubMed ID: 19181929
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute renal failure and its risk factors in Stevens-Johnson syndrome and toxic epidermal necrolysis.
    Hung CC; Liu WC; Kuo MC; Lee CH; Hwang SJ; Chen HC
    Am J Nephrol; 2009; 29(6):633-8. PubMed ID: 19155617
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Medications as risk factors of Stevens-Johnson syndrome and toxic epidermal necrolysis in children: a pooled analysis.
    Levi N; Bastuji-Garin S; Mockenhaupt M; Roujeau JC; Flahault A; Kelly JP; Martin E; Kaufman DW; Maison P
    Pediatrics; 2009 Feb; 123(2):e297-304. PubMed ID: 19153164
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Antigenic properties of blood serum in allergic dermatoses].
    Komov OP; Fedorovich SV; Fedorovich EI; Fedorov NI; Romanov VA
    Vestn Dermatol Venerol; 1973 Jul; 47(7):23-6. PubMed ID: 4757152
    [No Abstract]   [Full Text] [Related]  

  • 20. Evaluation of apoptotic cells and immunohistochemical detection of FAS, FAS-L, Bcl-2, Bax, p53 and c-Myc in the skin of patients with chronic venous leg ulcers.
    Heising S; Giebel J; Ostrowitzki AL; Riedel F; Haase H; Sippel K; Jünger M
    Int J Mol Med; 2008 Oct; 22(4):497-505. PubMed ID: 18813857
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.